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ABSTRACT
Introduction: Two novel agents, dabigatran and
rivaroxaban, recently gained market authorisation for
prevention of venous thromboembolism (VTE) after hip
and knee arthroplasty. However, safety data of the new
oral anticoagulants with a long-term use of 42 days are
not available for total knee arthroplasty (TKA).
Furthermore, there are no clinical trials comparing
dabigatran and/or rivaroxaban with nadroparin, which is
used in most Dutch departments of orthopaedic surgery.
Our aim is to compare the 42-day use of dabigatran and
rivaroxaban versus nadroparin after TKA in a clinical
explorative pilot study by assessing the incidence of
major bleeding and clinically relevant non-major bleeding
using a standardised model of bleeding definitions.
Methods and analysis: A randomised open-label pilot
study was conducted. Patients ≥18 years and weighing
more than 40 kg who were scheduled for a primary
elective TKA were included. Patients were randomly
assigned to three groups. Patients took either a daily oral
dose of dabigatran etexilate 220 mg (n=50), 10 mg of
oral rivaroxaban (n=50) or subcutaneous nadroparin
0.3 ml (n=50) for 42 days. The primary safety outcome
measure was the incidence of bleeding events. Major
bleeding events and clinically relevant non-major
bleeding events were defined according to accepted
guidelines. The secondary measures of this study were
the occurrence of VTE, time until the bleeding event,
compliance, duration of hospital stay, rehospitalisation,
outpatient clinic visits and interventions following
complications. Additionally, coagulation monitoring, knee
flexion range of motion and Knee injury and
Osteoarthritis Outcome Score were evaluated.
Dissemination: The results of this trial provided insight
into the validity of design for an adequately powered
multicentre study investigating the safety of the new oral
anticoagulants compared with nadroparin, an
anticoagulant applied for prevention of VTE after knee
arthroplasty in the Dutch situation.
Trial registration number: ClinicalTrials.gov:
NCT01431456.
INTRODUCTION
After total knee arthroplasty (TKA) surgery,
patients are at risk of developing venous
thromboembolism (VTE). Approximately
one-third of patients with symptomatic VTE
manifest pulmonary embolism (PE), whereas
two-thirds manifest deep venous thrombosis
(DVT) alone. Without thromboprophylaxis,
(venographic) DVT can be found in 40–80%
of patients.1 2 The risk of non-fatal and fatal
PE for TKA surgery patients without thrombo-
prophylaxis is 1.8–7.0% and 0.2–0.7%,
respectively.3 Hence, thromboprophylaxis is
indicated for all patients undergoing TKA.
Still, the choice of method raises discussion
because treatments that effectively prevent
VTE simultaneously increase the risk of bleed-
ing. Patients are, for example, at a higher risk
for bleeding when they have hypertension or
when they take medication that increases the
bleeding risk.4 5 Bleeding raises major safety
concerns for orthopaedic surgeons who pre-
scribe pharmacological thromboprophylaxis,
although the full clinical impact of VTE and
its status as a leading cause of preventable
death in hospitals remains under-rated.
It is very important to select the most appro-
priate thromboprophylaxis, by balancing the
risk of bleeding versus the prevention of VTE.
Recent research has focused on the devel-
opment of oral anticoagulants that can be
administered in ﬁxed dosages with the
expectation that they will provide safe and
effective alternatives to existing therapies.
Dabigatran etexilate (a direct thrombin
inhibitor) and rivaroxaban (a direct factor Xa
inhibitor) are new-generation oral anticoagu-
lants. Such new oral agents have already
shown efﬁcacy in large-scale clinical trials.6–9
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Both medicines have been approved for thromboprophy-
laxis after TKA in the European Union. Such new oral
agents have a rapid onset of action and can be given at
ﬁxed doses without the need for routine coagulation
monitoring.10
Meta-analysis comparing the efﬁcacy and safety of dabi-
gatran with enoxaparin suggests that these medicines
have a similar efﬁcacy and bleeding rate in patients
undergoing hip or knee arthroplasty.11 12 Huisman et al11
showed that enoxaparin is less effective than rivaroxaban
but has a lower risk of bleeding.
In clinical trials the new oral anticoagulants were
studied on efﬁcacy and safety with the comparator enox-
aparin, a low-molecular-weight heparin (LMWH) prepar-
ation.6–9 However, the external validity of such clinical
trials may be limited for Dutch knee replacement
surgery patients. Next to speciﬁc LMWH, also the dose
and duration vary in clinical practice. More importantly,
nadroparin is used in most Dutch departments of ortho-
paedic surgery after TKA for a treatment period of
42 days. Compared with 10–14 days in market authorisa-
tion for dabigatran and rivaroxaban, this is a much
longer treatment period.13 14
In this study we chose a treatment period of 42 days for
dabigatran, rivaroxaban and nadroparin. First, because a
treatment period of 42 days is in compliance with the
Dutch guidelines, these guidelines suggest applying prophy-
laxis with anticoagulants for 6 weeks after arthroplasty.15
Second, the information on prescription numbers of the
manufacturers of dabigatran and rivaroxaban, respectively
Boehringer Ingelheim and Bayer, shows that 80% of the
Dutch hospitals apply anticoagulants after TKA for a longer
treatment period than market authorisation for dabigatran
and rivaroxaban. Only 20% of the Dutch hospitals use dabi-
gatran and rivaroxaban, according to the market authorisa-
tion duration of 10–14 days. Different guidelines exist
regarding the prevention of VTE in orthopaedic surgery.
Previous surveys in the Netherlands have revealed that
guidelines regarding orthopaedic thromboprophylaxis
were not followed and that a wide variation in protocols
exists. Of the 84% of approached orthopaedic departments
in the Netherlands, 78% used prophylaxis with LMWH.
Eighty-ﬁve per cent of all these cases continued prophylaxis
for 42 days.16
Third, White et al17 suggested in their study that pro-
longed prophylaxis may be required, because less is known
about the incidence and time course of symptomatic DVT
or PE. The authors showed that the risk of developing a
DVTor PE decreases when prophylaxis is given for at least
35 days. Moreover, recent clinical trials have demonstrated
that more prolonged prophylaxis with LMWH after hos-
pital discharge signiﬁcantly reduces the incidence of veno-
graphically detected DVTafter arthroplasty.18
Given that dabigatran and rivaroxaban have market
authorisation on prophylaxis after total hip arthroplasty
for a treatment duration of 28–35 h, next to clinical
trials on the safety of dabigatran and rivaroxaban after
prophylaxis for 35 days after hip arthroplasty,19–21 we
expect a similar bleeding risk after 42 days of thrombo-
prophylaxis after TKA. Also the results of the clinical
trials on efﬁcacy and safety of dabigatran and rivaroxa-
ban for stroke prevention in atrial ﬁbrillation, with a
treatment period longer than 35 days, support the
choice and safety of longer treatment duration.22 23
Most orthopaedic departments in the Netherlands gen-
erally start perioperative prophylaxis with LMWH between
2 h before and 6 h after surgery. It appears that a pre-
operative start is no more effective than a postoperative
start. A perioperative start is apparently more effective, but
this is counterbalanced by a marked increase in the risk of
major bleeding in comparison with a preoperative or post-
operative regimen.16 That is the reason we chose post-
operative prophylaxis with nadroparin within 6 h after
surgery, like the speciﬁc departmental protocol on throm-
boprophylaxis. In order to prevent deviations in medica-
tion quality and safety in medication administration, all
three study medications were administered within 6 h after
TKA. The dose to be administered and the time of ﬁrst
administration of study medication were registered.
In randomised clinical trials the efﬁcacy of a new anti-
coagulant is typically assessed to establish LMWH prophy-
laxis. However, safety endpoint deﬁnitions applied in
these studies can vary. The wide range of deﬁnitions used
to classify bleeding outcomes in the studies makes it difﬁ-
cult to interpret the comparative bleeding risk associated
with the new anticoagulants.9 24
The objective of this study was to compare the 42-day
use of dabigatran and rivaroxaban versus nadroparin on
safety after TKA. This was an explorative, randomised,
open-label, pilot study that assessed the incidence of
major bleeding and clinically relevant, non-major bleed-
ing using a standardised model of deﬁnitions.25 The
purpose of this was to obtain insight into the design valid-
ity of an adequately powered multicentre study, investigat-
ing the safety of the new oral anticoagulants compared
with nadroparin, an anticoagulant applied for prevention
of VTE after knee arthroplasty in the Dutch population.
METHODS AND ANALYSIS
Study design
This study was an explorative open-label randomised
trial with a three-arm design. A total of 150 patients
were included, 50 patients in each treatment group
(dabigatran,rivaroxaban and nadroparin). Follow-up lasted
for 3 months after a treatment period of 42 days (in total
135 days). Table 1 presents the schedule of assessments and
procedures. This study was approved by the Medical Ethical
committee of the Medical Centre Leeuwarden.
Study population
The target population consisted of patients admitted to
the hospital for TKA. Patients ≥18 years and weighing
more than 40 kg who were scheduled for primary elect-
ive TKA and provided signed informed consent were eli-
gible for the study.
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Exclusion criteria
Patients were excluded if they met one of the following
exclusion criteria:
▸ A known inherited or acquired clinically signiﬁcant
active high risk of bleeding or bleeding disorder;
▸ Major surgery, trauma, uncontrolled severe arterial hyper-
tension or myocardial infarction within the last 3 months;
▸ A history of acute intracranial disease or haemor-
rhagic stroke;
▸ Gastrointestinal or urogenital bleeding or ulcer
disease within the last 6 months;
▸ Cirrhotic patients with moderate hepatic impairment
(aspartate or alanine aminotransferase levels higher
than 2× the upper limit of the normal range within
the last month);
▸ Severe renal insufﬁciency (creatinine clearance
<30 ml/min);
▸ Other indications for treatment with anticoagulants;
▸ Active malignant disease and
▸ Pregnancy or breastfeeding.
Outcomes
Main study endpoint
The primary endpoint of this study was the clinical
safety with a 42-day use of the oral once daily unmoni-
tored thrombin inhibitors dabigatran and rivaroxaban
versus subcutaneously administered nadroparin by
observing the incidence of major bleeding and clinically
relevant non-major bleeding in patients after knee
arthroplasty surgery.
Secondary study endpoints
The secondary endpoints of this study were the occur-
rence of clinical VTE (PE or DVT), time till the bleed-
ing event, compliance, duration of hospital stay,
rehospitalisation, outpatient clinic visits and interven-
tions following complications.
Other study parameters
The following patient characteristics were retrieved from
the hospital information system, the clinical pharmacy
information system or medical records:
▸ Demographics (age, sex and weight) and health char-
acteristics (kidney function/estimated glomerular ﬁl-
tration rate, liver function tests, comorbidity);
▸ Monitoring anticoagulant activity (anti-Xa activity),
activated partial thromboplastin time (aPTT), pro-
thrombin time (PT) and two validated clotting assays
developed to measure the anticoagulant activity of riv-
aroxaban and dabigatran;
▸ Knee ﬂexion range of motion, Knee injury and
Osteoarthritis Outcome Score (KOOS) scores,
obtained from orthopaedic documentation;
▸ Medication (time to ﬁrst dose of DVT-prophylaxis
postsurgery, use of NSAIDs, salicylates, SSRIs, clopido-
grel, anticoagulants such as VKAs).
Table 1 Schedule of assessments and procedures
Week
Outpatient




































Dosing info* At any time during the study
Bleeding events At any time during the study x
DVT or PE* At any time during the study x
Other adverse
events*
At any time during the study x
Knee flexion x x x
KOOS* x x
Compliance x
Survival At any time during the study
*Standard care.
DVT, deep venous thrombosis; KOOS, Knee injury and Osteoarthritis Outcome Score; PE, pulmonary embolism; TKA, total knee
arthroplasty.
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Sample size
This study was the ﬁrst pilot study designed to provide
estimates of the bleeding risks associated with the two
new anticoagulants dabigatran and rivaroxaban com-
pared with nadroparin in patients admitted to a Dutch
hospital for a TKA. The primary purpose was to gather
all the relevant information for designing a large-scale
multicentre conﬁrmatory clinical trial.
On the basis of the 2009 admission data of the
Department of Orthopaedic Surgery in our hospital, it is
expected that approximately 350 patients per year will
be admitted for a TKA. For the present exploratory pilot
study no formal power calculation was performed.
A total of 150 patients (50 patients in each arm) were
judged sufﬁcient for an initial assessment of bleeding
risks associated with the three study treatments, as well
as for gathering all relevant information for designing
and organising prior to a proposed larger multicentre
study.
With this sample size, an estimation of the probability
of observing bleeding events can be derived. Different
clinical trials on safety of the new oral anticoagulants
showed that around 3% of the patients developed a
major or non-major clinical bleeding event.11 26 27
Assuming this 3% bleeding rate, in our pilot study with
50 subjects per study arm, the probability of observing a
major bleeding in at least one patient in each of the
three treatment arms was 0.78. The probability of observ-
ing two patients with a bleeding event in one of the
treatment arms was 0.44.
Randomisation
Patients who met the inclusion criteria were informed
about the study, including the study treatments, risks
and possible adverse reactions, and the anticipated
period of treatment with one of the three prophylactic
anticoagulants.
After consenting to participate, patients were allocated
to one of the three study arms. At the start of the trial,
an independent hospital pharmacist of the local hospital
assigned the three medication sequences to a consecu-
tive series of numbers, using a computer-generated ran-
domisation list. On enrolment, each patient was
assigned to the next consecutive treatment number and
the corresponding study medication was dispensed in an
open-label manner. Orthopaedic surgeons were
informed about the treatment assignment of their
patient.
After closure of the clinical trial a blinded committee
adjudicated bleeding events independently by classifying
the observed bleeding using information provided by
the orthopaedic surgeon and the patient, as described
in box 1.
Interventions
Study procedures and the schedule of assessments are
displayed in table 1. Patients planning for a TKA surgery
were screened for eligibility. If a patient can potentially
be enrolled, he/she was informed about the trial and
asked to participate. Having consented to participate,
patients were included and received a study identiﬁca-
tion number, that is, were randomised.
Postoperatively, the patient received the allocated
thromboprophylaxis. Patients took either a daily oral
dose of dabigatran etexilate (two capsules of 110 mg)
220 mg (n=50) starting with a half-dose (110 mg) within
6 h after surgery (n=50) during 42 days, or 10 mg of oral
rivaroxaban once daily, starting within 6 h after surgery
during 42 days, or daily subcutaneous nadroparin
2850 IE/ml, 0.3 ml starting within 6 h after surgery
during 42 days. The dose to be administered and the
time of ﬁrst administration of study medication during
hospital stay were registered.
Patients received standard orthopaedic care (table 1),
which included KOOS28 and physiotherapy according to
the local standardised protocol. KOOS evaluates the
functional status and quality of life of patients with any
type of knee injury. Therefore, we wanted to measure
the clinical condition of patients before and after treat-
ment, to see if there was any difference in knee function
and quality of life between the treatment groups, nadro-
parin, rivaroxaban or dabigatran. We assume that there
will be a relation between clinical relevant (non)-major
bleeding and knee function. Physiotherapy was contin-
ued until patients reached a full range of motion and an
improvement in knee ﬂexion was achieved.
Box 1 Safety criteria for major and minor bleeding (clinic-
ally relevant non-major bleeding)
Major bleeding
▸ Fatal bleeding
▸ Clinically overt bleeding associated with a decrease in the
haemoglobin level of more than 20 g/l compared with the pre-
randomisation level
▸ Clinically overt bleeding leading to transfusion of ≥2 units of
whole blood or packed cells (according to the CBO guideline:
transfusion)
▸ Critical bleeding (intracerebral, intraocular, intraspinal, pericar-
dial or retroperitoneal)
▸ Bleeding warranting treatment cessation
▸ Bleeding located at the surgical site and leading to
re-operation or to any unusual medical intervention or proced-
ure for relief (eg, draining or puncture of a haematoma at the
surgical site, transfer to an ICU or emergency room)
Minor bleeding (ie, clinically relevant non-major bleeding)
▸ Spontaneous skin haematoma >25 cm2
▸ Wound haematoma >100 cm2
▸ Spontaneous nose bleeding or gingival bleeding lasting longer
than 5 min
▸ Spontaneous rectal bleeding creating more than a spot on
toilet paper
▸ Macroscopic haematuria either spontaneous or, if associated
with an intervention, lasting longer than 24 h
▸ Other bleeding events considered clinically relevant by the
investigator not qualifying as a major bleeding
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Every day during hospital stay the patient was exam-
ined. Speciﬁc attention was given to DVT, PE and bleed-
ing events. All major bleeding events and clinically
relevant non-major bleeding events were adjudicated
according to the standardised model of bleeding deﬁni-
tions25 (box 1).
After the required standard care, depending on per-
sonal recovery, the patient was discharged from the hos-
pital. At discharge, study medications were disposed for up
to 42 days after surgery. Patients were informed about the
possibility to contact their orthopaedic surgeon or
researcher about any adverse events they experienced
during or after the treatment with the anticoagulant (in
the home situation). On day 4 up until 6 after discharge
the patients were contacted daily by an orthopaedic nurse.
Bleeding events that occurred in the home situation were
all registered, and there was no loss to follow-up.
Patients returned to the outpatient clinic of the hos-
pital after 42 days. This follow-up visit with the ortho-
paedic surgeon included among other things wound
assessment, functional knee range of motion, presence
of signs or symptoms of VTE and occurrence of bleed-
ing events.
Three months event-free survival was examined and
patients were followed by a telephone interview on DVT
or PE adverse events and changes in concomitant medi-
cation during the period after treatment with the
anticoagulant.
Measurements
Measurements were completed during the preoperative
educational session as well as during the inpatient hos-
pital stay. Preoperative, patient demographics, medical
history and concomitant medication were registered.
Also blood chemistry, knee ﬂexion range of motion and
KOOS were measured.
Bleeding assessment
Major bleeding events and clinically relevant non-major
bleeding events were deﬁned according to accepted
guidelines (see box 1).25 Transfusions of ≥2 units of
whole blood or packed cells were given according to the
CBO guideline: Blood transfusion.29 Bleeding assess-
ment took place during the complete study period of
135 days. Any bleeding events that occurred perceived
by patients, researchers, nurses, orthopaedic surgeons or
other health workers were registered and deﬁned.
A blinded committee adjudicated bleeding events
independently by classifying the description and pictures
taken of the observed bleeding.
Efficacy
DVT or PE events that were registered by the ortho-
paedic surgeon were included in the database. Patients
were also informed about the possibility of contacting
the orthopaedic surgeon (in the home situation) about
any adverse events they experienced during or after
treatment with the anticoagulant.
Compliance
Compliance was measured by counting the amount of
randomised medication left over after 42 days of
treatment.
Coagulation monitoring
Coagulation monitoring was performed by measuring
anticoagulant activity (anti-Xa activity), aPTT, prothrom-
bin time (PT) and two validated clotting assays developed
to measure the anticoagulant activity of rivaroxaban and
dabigatran.
Knee function
Knee ﬂexion range of motion: the ﬂexion range of
motion was measured by a goniometer.
Knee injury and Osteoarthritis Outcome Score
The KOOS is a 42-item self-administered questionnaire
that includes ﬁve dimensions: pain, disease-related symp-
toms, activities of daily living function, sport and recre-
ation function, and knee-related quality of life measured
using a Likert scale (0–4 scale).
Surgery
According to hospital protocol, all the patients were
treated under the same surgical conditions, with the
same surgical techniques.
Follow-up: event-free survival and questionnaire
Three months event-free survival was reported and
patients were asked (by phone) about the DVT or PE
events, possible adverse events, changes in concomitant
medication and demographics during the period after
treatment with the anticoagulant.
Other measurements
The dose to be administered and the time of ﬁrst admin-
istration of study medication were registered.
Time till bleeding event, duration of hospital stay,
rehospitalisation, outpatient clinic visits and interven-
tions following complication were registered.
Statistical analysis
The primary analysis focused on risk of bleeding and
the occurrence of thromboembolic events in patients
treated with dabigatran, rivaroxaban or nadroparin.
The absolute bleeding risk was estimated as an incidence
rate with a 95% CI (under the Poisson distribution assump-
tion) for each treatment group. Differences between treat-
ment groups were assessed by Cox proportional hazard
regression analysis. In this, speciﬁc attention was given to
potential differences in the on-treatment versus off-
treatment period. Taking into account the single-centre
randomised study design, additional multivariable analysis
was not foreseen. Kaplan-Meier techniques were used to
depict the occurrence of bleeding events over time.
The incidence of thromboembolic events was assessed
using the same methodology.
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The analysis was based on the intention-to-treat prin-
ciple. Due to the explorative nature of this pilot study,
all p values were interpreted as explorative rather than
conﬁrmative.
DISSEMINATION
The results of this trial will provide insight into the validity
of design for an adequately powered multicentre study
investigating the safety of the new oral anticoagulants com-
pared to nadroparin, an anticoagulant applied for preven-
tion of VTE after knee arthroplasty in the Dutch situation.
Patient recruitment is expected to be ﬁnished by the
beginning of 2013.
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